SRS Capital Advisors Inc. Raises Stock Holdings in Zoetis Inc. (NYSE:ZTS)

Posted by Defense World Staff on Jun 17th, 2023

SRS Capital Advisors Inc. boosted its stake in shares of Zoetis Inc. (NYSE:ZTS – Get Rating) by 9.2% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,930 shares of the company’s stock after buying an additional 162 shares during the quarter. SRS Capital Advisors Inc.’s holdings in Zoetis were worth $283,000 as of its most recent SEC filing.

A number of other institutional investors have also made changes to their positions in ZTS. Trexquant Investment LP raised its position in Zoetis by 264.9% in the third quarter. Trexquant Investment LP now owns 32,166 shares of the company’s stock valued at $4,770,000 after purchasing an additional 23,352 shares during the period. Walkner Condon Financial Advisors LLC grew its stake in shares of Zoetis by 7.0% in the fourth quarter. Walkner Condon Financial Advisors LLC now owns 1,566 shares of the company’s stock valued at $229,000 after buying an additional 103 shares in the last quarter. Gyroscope Capital Management Group LLC purchased a new stake in shares of Zoetis in the 4th quarter valued at $264,000. O Shaughnessy Asset Management LLC lifted its stake in Zoetis by 50.3% during the 4th quarter. O Shaughnessy Asset Management LLC now owns 64,000 shares of the company’s stock worth $9,379,000 after acquiring an additional 21,408 shares in the last quarter. Finally, Centaurus Financial Inc. boosted its holdings in Zoetis by 5.3% during the 3rd quarter. Centaurus Financial Inc. now owns 2,804 shares of the company’s stock valued at $416,000 after acquiring an additional 142 shares during the period. 90.23% of the stock is currently owned by institutional investors and hedge funds.

Zoetis Trading Down 0.4 %

NYSE ZTS opened at $170.74 on Friday. Zoetis Inc. has a 52 week low of $124.15 and a 52 week high of $187.82. The firm has a 50 day moving average of $173.68 and a two-hundred day moving average of $164.93. The stock has a market capitalization of $78.90 billion, a PE ratio of 38.54, a price-to-earnings-growth ratio of 2.77 and a beta of 0.77. The company has a quick ratio of 1.94, a current ratio of 3.27 and a debt-to-equity ratio of 1.46.

Zoetis (NYSE:ZTS – Get Rating) last issued its earnings results on Thursday, May 4th. The company reported $1.31 EPS for the quarter, topping analysts’ consensus estimates of $1.27 by $0.04. The firm had revenue of $2 billion during the quarter, compared to the consensus estimate of $2.02 billion. Zoetis had a net margin of 25.59% and a return on equity of 50.26%. The company’s revenue was up .7% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $1.32 earnings per share. As a group, research analysts expect that Zoetis Inc. will post 5.4 EPS for the current fiscal year.

Zoetis Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Friday, September 1st. Stockholders of record on Friday, July 21st will be given a dividend of $0.375 per share. This represents a $1.50 annualized dividend and a dividend yield of 0.88%. The ex-dividend date is Thursday, July 20th. Zoetis’s dividend payout ratio (DPR) is presently 33.86%.

Insider Transactions at Zoetis

In other news, EVP Roxanne Lagano sold 4,338 shares of the firm’s stock in a transaction dated Tuesday, April 18th. The stock was sold at an average price of $175.94, for a total transaction of $763,227.72. Following the sale, the executive vice president now owns 26,357 shares of the company’s stock, valued at approximately $4,637,250.58. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 0.12% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on ZTS shares. StockNews.com initiated coverage on shares of Zoetis in a research note on Thursday, May 18th. They set a “buy” rating on the stock. Bank Of America (Bofa) increased their target price on shares of Zoetis from $180.00 to $200.00 and gave the stock a “buy” rating in a report on Tuesday, April 11th. Barclays raised their price target on shares of Zoetis from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Tuesday, February 21st. Finally, Piper Sandler cut their price objective on Zoetis from $220.00 to $210.00 in a research report on Monday, May 8th. Nine investment analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company presently has a consensus rating of “Buy” and an average target price of $221.14.

Zoetis Profile

(Get Rating)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.